Table 1 Demographics and clinical characteristics of sample, stratified by iron dosing (N=48,050)
Characteristics, mean (SD) or% | Bolus (13.9%) | Maintenance (49.3%) | Non-user (36.8%) |
|---|---|---|---|
Demographic | Â | Â | Â |
  Age, y | 60.1 (15.3) | 61.4 (15.1) | 61.4 (15.1) |
  Female | 45.8 | 45.1 | 45.3 |
  Race: White | 38.2 | 40.1 | 37.3 |
     Black | 56.7 | 54.1 | 56.8 |
     Other | 5.1 | 5.7 | 5.9 |
  Region: Midwest | 6.2 | 11.0 | 8.1 |
      Northeast | 80.6 | 84.3 | 78.6 |
      South | 10.6 | 2.8 | 9.6 |
      West | 1.8 | 1.4 | 3.0 |
Clinical | Â | Â | Â |
  Vintage, y | 4.8 (4.7) | 5.1 (5.0) | 5.8 (5.5) |
  Body Mass Index | 32.8 (23.5) | 33.9 (29.8) | 31.6 (24.7) |
  Catheter Use | 21.6 | 19.5 | 17.2 |
Laboratory and Anemia Management Variables | Â | Â | Â |
  Albumin at baseline | 3.84 (0.41) | 3.91 (0.37) | 3.93 (0.38) |
  Hemoglobin at baseline | 11.5 (1.4) | 12.0 (1.3) | 11.9 (1.4) |
  Index TSAT | 23.7 (9.5) | 31.4 (10.9) | 35.8 (14.3) |
  Ferritin at baseline | 625 (479) | 745 (536) | 862 (588) |
  Iron (mg) at baseline | 314 (316) | 279 (214) | 109 (241) |
  Iron (mg) during exposure | 700 (291) | 227 (118) | 0.0 (0.0) |
  EPO at baseline (1000U) | 111 (98) | 75.3 (78.3) | 62.0 (74.0) |
  EPO during exposure (1000U) | 113 (100) | 73.1 (77.0) | 63.0 (73.9) |
Comorbidities | Â | Â | Â |
   Hospital days in last month | 1.0 (2.3) | 0.6 (1.9) | 0.5 (1.8) |
   Infection in last month | 17.5 | 12.6 | 10.4 |
   Infection in last 6 mos. Pneumonia | 16.7 | 12.8 | 11.5 |
      Sepsis | 23.5 | 19.0 | 14.9 |
      Vascular access | 15.0 | 10.1 | 9.2 |
   Diabetes | 67.5 | 64.1 | 60.7 |
   Ischemic stroke | 16.7 | 12.9 | 12.5 |
   Myocardial Infarction | 6.2 | 4.4 | 4.0 |
   COPD, Asthma | 24.4 | 20.0 | 18.0 |
   Cancer | 12.1 | 10.9 | 11.7 |
   GI bleeding | 9.5 | 6.1 | 5.2 |